WO2004100949A3 - Solid-state forms of 5-(difluoromethoxy)-2-((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole (pantoprazole) sodium aqua complexes - Google Patents

Solid-state forms of 5-(difluoromethoxy)-2-((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole (pantoprazole) sodium aqua complexes Download PDF

Info

Publication number
WO2004100949A3
WO2004100949A3 PCT/IB2004/001590 IB2004001590W WO2004100949A3 WO 2004100949 A3 WO2004100949 A3 WO 2004100949A3 IB 2004001590 W IB2004001590 W IB 2004001590W WO 2004100949 A3 WO2004100949 A3 WO 2004100949A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid
difluoromethoxy
sulfinyl
pyridinyl
dimethoxy
Prior art date
Application number
PCT/IB2004/001590
Other languages
French (fr)
Other versions
WO2004100949A2 (en
Inventor
Darko Filic
Nada Kosutic Hulita
Aleksandar Danilovski
Miljenko Dumic
Zvonimir Siljkovic
Helena Ceric
Miroslav Zegarac
Original Assignee
Pliva Istrazivacki Inst D O O
Darko Filic
Nada Kosutic Hulita
Aleksandar Danilovski
Miljenko Dumic
Zvonimir Siljkovic
Helena Ceric
Miroslav Zegarac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Istrazivacki Inst D O O, Darko Filic, Nada Kosutic Hulita, Aleksandar Danilovski, Miljenko Dumic, Zvonimir Siljkovic, Helena Ceric, Miroslav Zegarac filed Critical Pliva Istrazivacki Inst D O O
Priority to EP04733398A priority Critical patent/EP1631284A2/en
Publication of WO2004100949A2 publication Critical patent/WO2004100949A2/en
Publication of WO2004100949A3 publication Critical patent/WO2004100949A3/en
Priority to HR20050963A priority patent/HRP20050963A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present disclosure relates to new solid-state forms of 5-(difluoromethoxy)--2-[[(3,4­dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium aqua complexes, and to processes for their preparation. The disclosure is also directed to pharmaceutical compositions containing the solid-state forms, and the methods of treatment using the solidstate forms.
PCT/IB2004/001590 2003-05-19 2004-05-17 Solid-state forms of 5-(difluoromethoxy)-2-((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole (pantoprazole) sodium aqua complexes WO2004100949A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04733398A EP1631284A2 (en) 2003-05-19 2004-05-17 Solid-state forms of 5-(difluoromethoxy)-2-((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole (pantoprazole) sodium aqua complexes
HR20050963A HRP20050963A2 (en) 2003-05-19 2005-11-18 New solid state forms of 5-(difluoromethoxy)-2-[[3,4-dimethoxy-2-pyridinil)methyl]sulfinyl]-1h-benzimidazole sodium aqua complexes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47203403P 2003-05-19 2003-05-19
US60/472,034 2003-05-19

Publications (2)

Publication Number Publication Date
WO2004100949A2 WO2004100949A2 (en) 2004-11-25
WO2004100949A3 true WO2004100949A3 (en) 2005-01-27

Family

ID=33452461

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/001590 WO2004100949A2 (en) 2003-05-19 2004-05-17 Solid-state forms of 5-(difluoromethoxy)-2-((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole (pantoprazole) sodium aqua complexes

Country Status (7)

Country Link
US (1) US20050004172A1 (en)
EP (1) EP1631284A2 (en)
CN (1) CN1791406A (en)
AR (1) AR044542A1 (en)
CL (1) CL2004001123A1 (en)
HR (1) HRP20050963A2 (en)
WO (1) WO2004100949A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514108A (en) 2002-12-19 2006-04-27 テバ ファーマシューティカル インダストリーズ リミティド Solid state of pantoprazole sodium, process for preparing them, and process for preparing known pantoprazole sodium hydrate
US20040235904A1 (en) * 2003-03-12 2004-11-25 Nina Finkelstein Crystalline and amorphous solids of pantoprazole and processes for their preparation
ITMI20040802A1 (en) * 2004-04-23 2004-07-23 Dinamite Dipharma S P A In For PANTOPRAZOLE POLYMORPHS SODIUM SALT AND PROCEDURE FOR THEIR PREPARATION
CN102584790B (en) * 2011-12-31 2014-04-02 江苏奥赛康药业股份有限公司 S-pantoprazole sodium trihydrate, and preparation method and application thereof
EP3187494A1 (en) 2015-12-30 2017-07-05 KRKA, tovarna zdravil, d.d., Novo mesto Process for the preparation of pantoprazole sodium sesquihydrate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533790A1 (en) * 1990-06-11 1993-03-31 Byk Gulden Lomberg Chem Fab New salt form.
CN1369491A (en) * 2002-02-10 2002-09-18 沈阳药科大学 Chiral pantorazole salt and its preparing process
WO2004056804A2 (en) * 2002-12-19 2004-07-08 Teva Pharmaceutical Industries Ltd. Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19843413C1 (en) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab New salt form of pantoprazole
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533790A1 (en) * 1990-06-11 1993-03-31 Byk Gulden Lomberg Chem Fab New salt form.
CN1369491A (en) * 2002-02-10 2002-09-18 沈阳药科大学 Chiral pantorazole salt and its preparing process
WO2004056804A2 (en) * 2002-12-19 2004-07-08 Teva Pharmaceutical Industries Ltd. Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Chiral salts of (5-difluoromethoxy-((3,4-dimethoxy-2-pyridyl)methyl)- sulfinyl)-1H -benzimidazole or pantoprazole, useful as a peptic ulce resistant medicine, and their preparation", DERWENT, 18 September 2002 (2002-09-18), XP002264331 *
BADWAN A A ET AL: "PANTOPRAZOLE SODIUM", ANALYTICAL PROFILES OF DRUG SUBSTANCES, vol. 29, no. 1, 24 January 1997 (1997-01-24), pages 185 - 192, XP008031282 *
KOHL, B. ET AL.: "(H+,K+)-ATPase Inhibiting 2-[(2-Pyridylmethyl)sulfinyl]benzimidazoles. 4. A Novel Series of Dimethoxypyridyl-Substituted Inhibitors with Enhanced Selectivity. The Selection of Pantoprazole as a Clinical Candidate", J. MED. CHEM., vol. 35, 1992, pages 1049 - 1057, XP002293471 *

Also Published As

Publication number Publication date
CL2004001123A1 (en) 2005-04-22
CN1791406A (en) 2006-06-21
US20050004172A1 (en) 2005-01-06
EP1631284A2 (en) 2006-03-08
AR044542A1 (en) 2005-09-21
HRP20050963A2 (en) 2007-02-28
WO2004100949A2 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
WO1998054171A8 (en) Novel form of s-omeprazole
EP1186602A3 (en) Omeprazole sodium salt and its use as anti-ulcer agent
WO2006034315A3 (en) Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
WO2006034446A3 (en) Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
ATE391126T1 (en) CRYSTALLINE FORM OF (R)-2-(((3-METHYL-4-(2,2,2-TRIFLUORETHOXY)-2-PYRIDINYL)METHYL)SULFINYL)-1H BENZIMIDAZOLE
SE9900274D0 (en) New compound
WO2006034341A3 (en) Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
MX2007003327A (en) Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase.
DE69922676D1 (en) N-ARALKYLAMINOTETRALINES AS NEUROPEPTIDE Y-Y5 RECEPTOR LIGANDS
NO20023313D0 (en) Newly substituted benzimidazole dosage forms and methods for using the same
HK1069168A1 (en) Improved process for preparing benzimidazole-type compounds
CL2009000805A1 (en) Pharmaceutical composition comprising a sodium salt of the (-) enantiomer of 5-methoxy-2 [[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfinyl] -1h-benzimidazole ((-) - omeprazole ); and its use in the inhibition of gastric acid secretion and to treat gastrointestinal inflammatory diseases. (divisional application 3570-00).
HRP20090340T1 (en) 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases
IL172266A0 (en) Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
HRP20010117A2 (en) Novel salt form of pantoprazole
WO2006125181A3 (en) Piperidine derivatives and their use as stearoyl-coa desaturase modulators
WO2003006670A3 (en) 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
ZA989999B (en) New process for the preparation of 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)1H-benzimidazole
HRP20030853A2 (en) Crystalline form of omeprazole
WO2004100949A3 (en) Solid-state forms of 5-(difluoromethoxy)-2-((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole (pantoprazole) sodium aqua complexes
WO2003027098A1 (en) Benzimidazole compound, process for producing the same, and use thereof
AU2000258410A8 (en) New method for the preparation of the anti-ulcer compounds omeprazole, lansoprazole and pantoprazole
WO2002076400A3 (en) Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
YU32301A (en) New crystalline form of omeprazole
MY118724A (en) New crystalline form of omeprazole

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: P20050963A

Country of ref document: HR

Ref document number: 20048137278

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004733398

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004733398

Country of ref document: EP